Lenalidomide Grindeks

Lenalidomide, the active ingredient in Lenalidomide Grindeks, is an immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It is indicated for the treatment of multiple myeloma and selected myelodysplastic syndromes in adult patients, where it helps control disease progression and reduce dependence on blood transfusions.

GNH USA supplies Lenalidomide Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global distribution, and supporting regulatory compliance for importers.

Lenalidomide is used in hematologic malignancies and related bone‑marrow disorders, targeting abnormal plasma‑cell proliferation and ineffective hematopoiesis. - Multiple myeloma: improves progression‑free survival and reduces disease burden in adult patients. - Myelodysplastic syndromes with del(5q): decreases transfusion dependence and can achieve cytogenetic remission. - Relapsed or refractory multiple myeloma: provides therapeutic benefit after prior therapies have failed.

Lenalidomide may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count leading to infection risk. - Thrombocytopenia: low platelet levels increasing bleeding tendency. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may require supportive care.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: markedly low neutrophils requiring medical intervention. - Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions.

When prescribing Lenalidomide, clinicians should observe several precautionary measures to minimize risks. - Monitor blood counts: perform regular complete blood count assessments. - Assess thrombotic risk: evaluate patient history for clotting disorders before therapy. - Evaluate renal function: adjust use in patients with impaired kidney function. - Contraindicated in pregnancy: avoid use in pregnant women due to potential fetal harm. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomide can interact with other medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase lenalidomide exposure. - Anticoagulants (e.g., warfarin): heightened risk of thrombosis or bleeding. - Live vaccines: immunosuppression may reduce vaccine effectiveness.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin): may lower drug levels. - NSAIDs: combined use may increase renal toxicity. - Diuretics: may affect electrolyte balance and renal function.